Research
Minocycline fails to modulate cerebrospinal fluid HIV infection or immune activation in chronic untreated HIV-1 infection: results of a pilot study
-
* Corresponding author: Richard W Price rwprice@sfgh.ucsf.edu
1 Department of Neurology1 University of California San Francisco, San Francisco, CA, USA
2 Division of Biological Chemistry, Biocentre, Innsbruck Medical University, Innsbruck, Austria
3 Division of Experimental Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA
4 Department of Neurology, University of Washington, Seattle, WA, USA
5 Department of Neurology, Yale University, New Haven, CT, USA
AIDS Research and Therapy 2011, 8:17 doi:10.1186/1742-6405-8-17
Published: 12 May 2011Abstract
Background
Minocycline is a tetracycline antibiotic that has been shown to attenuate central nervous system (CNS) lentivirus infection, immune activation, and brain injury in model systems. To initiate assessment of minocycline as an adjuvant therapy in human CNS HIV infection, we conducted an open-labelled pilot study of its effects on cerebrospinal fluid (CSF) and blood biomarkers of infection and immune responses in 7 viremic subjects not taking antiretroviral therapy.
Results
There were no discernable effects of minocycline on CSF or blood HIV-1 RNA, or biomarkers of immune activation and inflammation including: CSF and blood neopterin, CSF CCL2, CSF white blood cell count, and expression of cell-surface activation markers on CSF and blood T lymphocytes and monocytes.
Conclusions
This pilot study of biological responses to minocycline suggests little potential for its use as adjunctive antiviral or immunomodulating therapy in chronic untreated HIV infection.